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Background: The endothelial progenitor cell (EPC) plays an important role in repairing vascular injury.
Statins and angiotensin II receptor blockers increase the level of circulating EPCs. However, it is unknown
whether the angiotensin II receptor blocker olmesartan synergistically acts with statins to increase the
levels of circulatingEPCs.Moreover, the associationbetween the levels of circulatingEPCs andendothelial
dysfunction after implantation of drug-eluting stents (DESs) has not been evaluated.
Methods: Nine patients with stable coronary artery disease underwent percutaneous coronary interven-
tion (PCI) and received DES implantation. All patients received olmesartan in addition to statin therapy
after PCI. The dose of olmesartan was based on the physician’s discretion as per the patients’ blood
pressure. The levels of circulating EPCs were analyzed at baseline, post-PCI, and 1, 2, 3, and 8 months
after PCI. Coronary angiography and the acetylcholine provocation test were performed on all patients at
8 months.
Results: Although the angiotensin II level signiﬁcantly changed, the levels of circulating EPCs did not
change during 8 months of olmesartan treatment (3.1±0.6 cells/ml, 2.5±0.8 cells/ml, 2.0±0.6 cells/ml,
2.9±0.9 cells/ml, 3.0±0.4 cells/ml, 3.4±0.8 cells/ml, p=0.64). The patients were subsequently divided
into two groups based on whether the level of circulating EPCs was less or greater than 4 cells/ml at
8 months. There were no signiﬁcant differences in the mean vessel diameter of each segment (proximal,
proximal edge, distal edge, and distal) after the acetylcholine provocation test between the two groups.
Conclusions: Low-to-moderate doses of olmesartan might not increase the level of circulating EPCs in
patients receiving statin therapy. Theremight beno associationbetween the levels of circulating EPCs and
the degree of coronary vasospasm in the acetylcholine provocation test 8months after DES implantation.
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Circulating endothelial progenitor cells (EPCs) play an impor-
ant role in repairing vascular injury through rapid endothelial
egeneration [1,2]. EPCs are a key component of vascular healing
fter percutaneous coronary intervention (PCI) [3]. Nonetheless,
ardiovascular risk factors are associated with reduced number of
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circulating EPCs [4–7]. Statins and certain antihypertensive drugs,
such as angiotensin II receptor blockers (ARBs), increase the lev-
els of circulating EPCs [4,8–11]. Atorvastatin increases the level of
circulating EPCs by a factor of 3 in patients with stable coronary
artery disease [8]. Olmesartan also increases the level by a factor
of 2 in patients with type II diabetes [11]. However, to the best
of our knowledge, no data are available on whether these drugs
act synergistically. Therefore, we evaluated the effect of olmesar-
tan on the level of circulating EPCs after PCI in patients receiving
statin therapy. Because endothelial dysfunction can occur follow-
ing the implantation of drug-eluting stents (DESs), we investigated
whether this adverse event is associated with the number of circu-
lating EPCs.
served.
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atients and study protocol
Nine patients with stable coronary artery disease underwent
CI, and DES was implanted in the lesion. Angiotensin-converting
nzyme inhibitors and ARBs were not prescribed before PCI;
owever, statins were prescribed at least 3 months before the pro-
edure for all patients [atorvastatin 10mg/day (n=3), rosuvastatin
.5mg/day (n=2), rosuvastatin 5mg/day, rosuvastatin 10mg/day,
itavastatin 1mg/day, and pitavastatin 2mg/day (n=1)]. Olme-
artan was started after PCI, and the dose was based on the
hysician’s discretion according to the patient’s blood pressure.
e determined the number of circulating EPCs (baseline, post-PCI,
nd after 1, 2, 3, and 8 months) and the levels of angiotensin II
baseline, 1, 3, and 8 months), inteleukin-6 (IL-6), tumor necro-
is factor- (TNF-), monocyte chemotactic protein-1 (MCP-1),
nd P-selectin (baseline, post PCI, and after 1, 3, and 8 months).
ollow-up coronary angiography and the acetylcholine provo-
ation test were performed at 8 months for all patients. The
rimary endpoint of the present study was the level of circulat-
ng EPCs during 8 months. Hypertension was deﬁned as systolic
lood pressure ≥140mmHg, diastolic blood pressure ≥90mmHg
r use of an antihypertensive drug. Dyslipidemia was deﬁned
s low-density lipoprotein cholesterol >100mg/dl, high-density
ipoprotein cholesterol ≤50mg/dl, triglycerides ≥150mg/dl, or
edication use. This study was reviewed and approved by the
ocal Ethics Review Committee, and written informed consent was
btained from all patients.
nterventional protocol and quantitative coronary analysis
All interventions were performed using standard techniques.
he type of DES was chosen according to the physician’s dis-
retion. All patients were advised to continue treatment with
ual antiplatelet therapy (aspirin 100mg/day and clopidogrel
5mg/day) for 12months after PCI and lifelong daily use of aspirin.
he acetylcholine provocation test was performed along with
ollow-up angiography after 8 months. After baseline angiogra-
hy, incremental doses of acetylcholine (50 and 100g/20 s into
he left coronary artery and 25 and 50g/20 s into the right coro-
ary artery) were infused directly through the catheter. After an
Fig. 1. The number of endothelial progenitor cells was determined using ﬂlogy 64 (2014) 435–440
additional 5min, intracoronary isosorbidedinitrate (5mg/10 s)was
infused into the right and left coronary arteries. Qualitative and
quantitative coronary angiography was evaluated at an indepen-
dent angiographic core laboratory (Cardiocore, Tokyo, Japan) using
a Coronary Angiography Analyses System (Medis QAngio XA 7.1,
Leiden, The Netherlands). Baseline, post-procedure, and follow-up
angiograms were obtained from all patients. The target segment
was deﬁned as the entire segment involving the implanted stent
and the5-mmproximal anddistal edges adjacent to the stent. In the
acetylcholine provocation test, a reference vessel not related to the
stent lesionwasanalyzed (5–15mmproximal anddistal to the stent
edges). We divided the enrolled patients into two groups based on
the level of circulating EPCs (4 cells/ml) and compared the results
of the acetylcholine provocation test between the two groups.
Level of circulating EPCs
A 20-ml sample of peripheral blood was obtained from each
patient, and the number of circulating EPCswas determinedwithin
24h (SRL, Tokyo, Japan) using a ﬂuorescence-activated cell sorter
(FACScan, Becton Dickinson, Franklin Lakes, NJ, USA). EPCs were
identiﬁed by the presence of CD34, CD45, CD133, and CD133 anti-
gens (Fig. 1).
Statistics
Continuous variables are expressed as mean± standard devia-
tion (SD) and compared using Student’s t test. The values for all
blood samples for all time points were compared using repeated
measure analysis of variance (ANOVA). All statistical tests were
two-tailed. Statistical signiﬁcance was deﬁned as p=0.05.
Results
Baseline characteristics and outcomes
Nine patients were enrolled in this study. Table 1 presents their
baseline characteristics. Their mean age was 70 years. All patients
had dyslipidemia and received statin therapy at least 3 months
before the procedure. Patients received 40mg (n=3) or 20mg
doses (n=6) of olmesartan during follow-up. Lesion and procedural
characteristics are presented in Table 2. Sirolimus-eluting and
ow cytometry to detect CD34, CD45, CD133, and VEGFR2 antigens.
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Table 1
Patient baseline characteristics.
N=9
Age 70.0±10.4
Male 6 (66.7%)
Hypertension 6 (66.7%)
Dyslipidemia 9 (100%)
Family history of CAD 2(22.2%)
Diabetes mellitus 2 (22.2%)
Smoking 4 (44.4%)
Multi-vessel disease 4 (44.4%)
Creatine (mg/dl) 0.78±0.15
eGFR (ml/min) 68.9±7.9
LDL (mg/dl) 100.6±32.3
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AD, coronary artery disease; eGFR, estimated glomerular ﬁltration rate; LDL, low
ensity lipoprotein; CRP, C-reactive protein.
verolimus-eluting stentswere implanted in four and ﬁve patients,
espectively.
umber of circulating EPCs and levels of inﬂammation markers
During 8 months, the angiotensin II levels changed sig-
iﬁcantly (6.6±1.1pg/ml, 14.0±3.4pg/ml, 24.6±9.0pg/ml,
.2±1.1pg/ml, p=0.02, Fig. 2) but the level of circulating EPCs did
ot change (3.1±0.6 cells/ml, 2.5±0.8 cells/ml, 2.0±0.6 cells/ml,
.9±0.9 cells/ml, 3.0±0.4 cells/ml, 3.4±0.8 cells/ml, p=0.64;
ig. 3A). The number of circulating EPCs increased in four patients
nd decreased in ﬁve patients at 8months comparedwith baseline
Fig. 3B). The levels ofMCP-1 signiﬁcantly changedduring8months
ecause of the low level after the procedure (Fig. 4). In contrast, the
evels of IL-6, TNF-, and P-selectin did not signiﬁcantly change
uring follow-up (Fig. 4).
uantitative coronary angiography and acetylcholine provocation
est
All patients underwent coronary angiography at 8 months,
nd the mean in-stent and in-segment late luminal losses were
.05±0.40mmand 0.03±0.42mm, respectively. Binary restenosis
as not detected in any patient (Table 3). When the patients were
ivided into two groups based on the level of circulating EPCs at
months (EPC level greater or less than 4 cells/ml), the change
able 2
esion and procedural characteristics.
N=9
Treated vessel
RCA 1(11.1%)
LAD 3(33.3%)
LCX 5(55.5%)
Lesion type
A 0 (0%)
B1 1 (11.1%)
B2 6 (66.6%)
C 2 (22.2%)
Bifurcation lesion 6 (66.6%)
Diffuse lesion 2 (22.2%)
Pre
Lesion length (mm) 18.04±7.69
Reference vessel diameter (mm) 2.60±0.66
Minimal lumen diameter (mm) 0.82±0.26
Diameter stenosis (%) 67±12
DES type
Sirolimus 4 (44.4%)
Everolimus 5 (55.5%)
Average stent diameter (mm) 3.01±0.32
Average stented length (mm) 25.2±7.9
Stent/lesion 1.2±0.4
CA, right coronary artery; LCX, left circumﬂex artery; LAD, left anterior descending
rtery.Fig. 2. Changes in angiotensin-II levels. The angiotensin II level increased during
the ﬁrst 3 months of treatment and decreased at 8 months.
(%) in the mean vessel diameter after intracoronary acetylcholine
and isosorbide dinitrate injections did not signiﬁcantly change for
each segment (proximal, proximal edge, distal edge, and distal seg-
ments) between the two groups (Fig. 5).
Discussion
The principal ﬁndings of the present study are that low-to-
moderate doses of olmesartan did not have a synergistic effectwith
statins to increase the level of circulating EPCs in patients receiving
statin therapy, and there was no association between the number
of circulating EPCs and the degree of coronary vasospasm detected
using the acetylcholine provocation test after DES implantation.
ARBs lower blood pressure and induce pleiotropic effects,
including anti-inﬂammation [12]. One mechanism that accounts
for these pleiotropic effects may be increasing the level of circulat-
ing EPCs. Angiotensin II accelerates the onset of EPC senescence by
increasing GP91-PHOX levels through activation of the angiotensin
II receptor [13]. Further, angiotensin II promotes the vascular
endothelial growth factor-induced proliferation and network for-
mation of human EPCs [14]. ARBs have the potential to delay
EPC senescence and promote EPC proliferation. Olmesartan signiﬁ-
cantly reduced the expression of vascular-inﬂammation markers
(high sensitivity C-reactive protein, IL-6, MCP-1, and TNF-) in
patientswithessential hypertensionandsigniﬁcantly increased the
number of circulating EPCs in patientswith type II diabetes [11,12].
However, we did not detect these effects in this study.
These results may be explained as follows. First, we enrolled
patients receiving statin therapy. Statins reduce inﬂammation and
increase the number of circulating EPCs [4], and the mechanisms
responsible for these effects may be shared by statins and ARBs.
Therefore, the effect of olmesartan is eliminated in patients receiv-
ing statin therapy. Second, in a previous study, an increased EPC
levelwas observed in patientswith type II diabetes patients but not
in healthy subjects [11]. The prevalence of diabetes was only 20%
in our study. Third, our study used either 20mg or 40mg olmesar-
tan compared with 80mg in the previous study [11]. Although the
angiotensin II level signiﬁcantly changed, this dose may have been
insufﬁcient to increase the number of circulating EPCs. High doses
of olmesartan may be required to increase the level of circulat-
ing EPCs, particularly in patients who have already received statin
therapy. Fourth, ARBs theoretically improve the level of circulating
EPCs [12–14]. Other ARBs might increase the level of circulating
EPCs even in patients on statin therapy.
Patients often experience vascular dysfunction following DES
implantation [15,16]. Angina sometimes occurs in these patients
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oig. 3. (A) Change in the level of circulating endothelial progenitor cells (EPCs). The
aseline and 8 months in each patient. The level of circulating EPCs increased in fou
ithout in-stent restenosis, and severe coronary spasms can be
ife-threatening [17,18]. These adverse effects of a DES implant are
elated to endothelial dysfunction [19]. However, to the best of
ur knowledge, there is no report investigating the predictors of
ndothelial dysfunction after DES implantation.Circulating EPCs mediate ongoing endothelial repair. The level
f circulating EPCs may serve as a surrogate biologic marker for
ascular endothelial function [6]. We hypothesized that the num-
er of circulating EPCs determines whether vascular dysfunction
ig. 4. Changes in interleukin-6 (A), tumor necrosis factor- (B), monocyte chemotactic
nly for MCP-1. PCI, percutaneous coronary intervention.of circulating EPCs did not signiﬁcantly change. (B) The level of circulating EPCs at
ents and decreased in four patients. PCI, percutaneous coronary intervention.
occurs after DES implantation. However, in this study of a small
number of patients, the level of circulating EPCs was not associ-
ated with vascular dysfunction indicated using the acetylcholine
provocation test. Considering the average level of circulating EPCs
in the present study (3.4 cells/ml), we deﬁned the cut-off point as
4 cells/ml. A larger number of circulating EPCs may be required
to prevent vascular dysfunction after DES implantation. Another
possibility is that there is no association between the level of
circulating EPCs and vasospastic response. To the best of our
protein-1 (MCP-1) (C), and P-selectin (D) levels. A signiﬁcant change was observed
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Table 3
Quantitative coronary angiography results.
In-lesion Proximal edge In-stent Distal edge
Reference diameter
Post-procedure (mm) 2.99±0.60 3.28±0.51 3.13±0.52 2.76±0.57
Follow-up (mm) 3.06±0.70 3.37±0.46 3.09±0.65 2.79±0.63
Minimal lumen diameter
Post-procedure (mm) 2.26±0.67 2.79±0.57 2.49±0.60 2.29±0.69
Follow-up (mm) 2.23±0.62 2.77±0.63 2.43±0.59 2.23±0.66
Percent diameter stenosis
Post-procedure (%) 25±10 15±8 21±10 18±13
Follow-up (%) 28±7 19±9 21±10 20±13
Late loss (mm) 0.03±0.42 0.02±0.18 0.05±0.40 0.06±0.15
Binary restenosis rate (%) 0 0 0 0
Fig. 5. Percentage change in mean vessel diameter after intracoronary acetylcholine (Ach) and isosorbide dinitrate (IC-ISDN) injections. The nine patients were divided into
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nowledge, no study showed the association between the level of
irculating EPCs and vasospastic response following DES implan-
ation to date. A further larger study is warranted to evaluate this
ossibility.
There are several limitations to the present study. First, the sam-
le size is small and statistically insufﬁcient for comparing the two
roups. As the protocol, we planned to enroll 15 patients in this
tudy from April 2009 to March 2010. Although we extended the
nrollment until March 2011, nine patients were ﬁnally enrolled.
hus the results should be considered exploratory and hypothesis
enerating. Second, the analysis of the level of circulating EPCs is
urrently not uniﬁed [4]. Therefore, the number of circulating EPCs
annot be generalized, and it is not possible to compare their num-
ers determined in this study with those reported in other studies.
or example, ﬂow cytometry and/or colony-forming assays have
een used. Further, several cell-surface markers are used to iden-
ifyEPCs, includingCD45,CD14,CD117,CD133,CD34,CD31,CD105,
ie-2, and KDR. Finally, there were differences in the types of stent
nd the types and doses of statins administered to our patients,
hich may have differentially affected the level of circulating EPCs
n each patient. However, to the best of our knowledge, the present
tudy is the ﬁrst to consecutively (six times) analyze the number of
irculating EPCs before and after PCI and to evaluate the association
etween the level of circulating EPCs and vascular response in the
cetylcholine test.three patients in the high group, and six patients in the low group). There were no
Conclusions
Moderate-to-low doses of olmesartan did not synergize with
statins to increase the level of circulating EPCs in patients receiv-
ing statin therapy. There was no association between the level
of circulating EPCs and the degree of coronary vasospasm in the
acetylcholine provocation test 8 months after DES implantation.
A further larger study is warranted to evaluate the association
between the number of circulating EPCs and vascular dysfunction
following DES.
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